raf kinase inhibitors (Onyx/Bayer)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameraf kinase inhibitors (Onyx/Bayer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRAF serine/threonine protein kinase inhibitors
TargetsRAF serine/threonine protein kinase
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOnyx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOnyx Pharmaceuticals IncBayer AG
Active IndicationsN/A
Inactive IndicationsPsoriasisArthritis, RheumatoidNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A